

CORDLIFE GROUP LIMITED
(Company Registration No. 200102883E)
(Incorporated in the Republic of Singapore)

ANNOUNCEMENT PURSUANT TO RULE 706A OF THE SGX-ST LISTING MANUAL

Pursuant to Rule 706A of the Listing Manual of the Singapore Exchange Securities Trading Limited, Cordlife Group Limited (the "**Company**"), and together with its subsidiaries, the "**Group**") wishes to announce the following transactions that occurred during the half year ended 30 June 2021:

1. ACQUISITION OF SHARES RESULTING IN INCREASE IN SHAREHOLDING PERCENTAGE IN A SUBSIDIARY

On 11 June 2021, the Company, through its wholly-owned subsidiary, Cordlife Stem Cell Technology Limited ("**CLSC**"), acquired (the "**Acquisition**") an additional 660,000 ordinary shares (the "**HKSC Acquisition Shares**") in Hong Kong Screening Centre Limited ("**HKSC**"), representing approximately 33% of the total number of issued shares of HKSC, from Navigene Genetic Science Pvt. Ltd ("**NGS**"), for a consideration of HK\$329,776 (approximately S\$57,055 based on an illustrative exchange rate of HK\$5.78 : S\$1.00 (the "**Illustrative Exchange Rate**") (the "**Consideration**"). Prior to the Acquisition, the remaining 67% stake in HKSC was held by CLSC. With the completion of the Acquisition, HKSC is now an indirect wholly-owned subsidiary of the Company.

The Consideration was arrived at after arm's length negotiations between CLSC and NGS on a willing-buyer and willing-seller basis after taking into account factors such as the net liability position of HKSC as well as potential tax savings for the Group resulting from the Acquisition. The Consideration, less HK\$17,000 (approximately S\$2,941 based on the Illustrative Exchange Rate) (being NGS' contribution towards CLSC's legal costs as agreed in the sale and purchase agreement relating to the Acquisition (the "**SPA**")), was paid in cash on 16 June 2021 in accordance with the terms of the SPA and was funded by internal sources of funds. Based on the latest management accounts of the Group as at 31 May 2021, the net liability value of the HKSC Acquisition Shares was approximately HK\$903,068 (approximately S\$156,240 based on the Illustrative Exchange Rate).

The Acquisition is not expected to have any material impact on the net tangible assets and net earnings per share of the Group for the financial year ending 31 December 2021. None of the Directors or controlling shareholders of the Company has any interest, direct or indirect, in the Acquisition.

2. DISSOLUTION OF SUBSIDIARY

As announced on 8 April 2021, the Company's application to Suruhanjaya Syarikat Malaysia (Companies Commission of Malaysia) ("**SSM**") to dissolve its dormant, indirect majority-owned subsidiary incorporated in Malaysia, SL Diagnostics Sdn. Bhd. ("**SLD**") has been approved by SSM and SLD was dissolved under Section 550 of the Malaysian Companies Act 2016. The dissolution of SLD is not expected to have any

material impact on the net tangible assets and net earnings per share of the Group for the financial year ending 31 December 2021.

For and on behalf of the Board
CORDLIFE GROUP LIMITED

Tan Poh Lan
Group CEO and Executive Director
13 August 2021